Clincosm LogoSign in Get a demo

Texture Features and PDL1 in CT-PET 18 FDG

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Completed
CT.gov ID
NCT04309422
Collaborator
(none)
84
Enrollment
1
Location
22
Actual Duration (Months)
3.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Search correlation between texture features in CT-PET 18 FDG and overexpression of PDL1 in non-small cell lung carcinomas during the inital staging.

The hypothesis is that overexpression of PDL1is correlated with at least one texture feature among those selected.

84 CT-PET 18 FDG at the initial staging of a non small cell lung carcinoma (adenocarcinoma or squamous cell carcinoma), whose the biopsed site was the primitive site or the drainage lymphadenopathy, without previous treatment, were recruited and analyzed by a software allowing to estimate texture features.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    84 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Correlation Between Texture Features With CT-PET 18 FDG and Overexpression of PDL1 in Non-small-cell Lung Carcinomas During the Initial Staging.
    Actual Study Start Date :
    Apr 1, 2018
    Actual Primary Completion Date :
    Oct 1, 2018
    Actual Study Completion Date :
    Jan 31, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    Overexpression of PDL1

    Overexpression of PDL1
    Absence of overexpression of PDL1

    Absence of overexpression of PDL1

    Outcome Measures

    Primary Outcome Measures

    1. Correlation between at least one texture feature and overexpression of PDL1 [1 day]

      Correlation between at least one texture feature and overexpression of PDL1

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion criteria:

    • adult patient ;

    • first CT-PET 18 FDG realized for the inital staging ;

    • absence of previous treatment for a thoracic neoplasm ;

    • biopsy realized on the primitive site or local drainage lymphadenopathy ;

    • primitive site viewable with morphological imagery ;

    • availability of evaluation of PDL1's overexpression ;

    Exclusion criteria

    • Refusal to participate in this research

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Uh Montpellier Montpellier France 34295

    Sponsors and Collaborators

    • University Hospital, Montpellier

    Investigators

    • Principal Investigator: Jean-Baptiste MALLET, University Hospitals of Montpellier

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Montpellier
    ClinicalTrials.gov Identifier:
    NCT04309422
    Other Study ID Numbers:
    • RECHMPL19_0623
    First Posted:
    Mar 16, 2020
    Last Update Posted:
    Mar 18, 2020
    Last Verified:
    Mar 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Montpellier
    Correlation between overexpression of PDL1
    texture features
    CT-PET 18 FDG
    Non Small Cell Lung Carcinoma
    Additional relevant MeSH terms:
    Carcinoma, Non-Small-Cell Lung

    Study Results

    No Results Posted as of Mar 18, 2020